Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2020-09-18 Earnings Release
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release from Ipsen dated September 18, 2020, announcing the release of first efficacy and safety data from the CLARINET FORTE study, which was presented at the ESMO 2020 Congress. It details clinical trial results (PFS, safety signals) for the drug Somatuline® Autogel® (lanreotide) in treating Neuroendocrine Tumors (NETs). This content is characteristic of an initial announcement of periodic financial/clinical results, focusing on key highlights rather than a comprehensive report or a transcript of a call. It aligns best with the 'Earnings Release' (ER) definition, which covers initial announcements of periodical results, even though this is clinical data rather than strictly financial earnings, as it serves the same function of informing the market about recent performance/developments. It is not a full 10-K, an IR report, or a Call Transcript (CT). Given the context of clinical trial data release coinciding with a major medical congress, it functions as a key periodic update. FY 2020
2020-09-18 English
Inside Information / Other news releases
Transaction in Own Shares Classification · 1% confidence The document explicitly states 'Disclosure of transactions in own shares' and provides a detailed table showing daily volume and weighted average price for transactions occurring between 09/07/2020 and 09/11/2020. This directly corresponds to the definition of a report detailing the company buying back or selling its own shares. The appropriate filing code is POS (Transaction in Own Shares). The document is a direct report of the transactions, not an announcement of a report, so RPA/RNS is not applicable.
2020-09-15 English
Informations privilégiées / Autres communiqués
Transaction in Own Shares Classification · 1% confidence The document title is "Déclaration des transactions sur actions propres réalisées du 07/09/2020 au 11/09/2020" (Declaration of transactions on own shares carried out from 07/09/2020 to 11/09/2020). The content is a detailed table showing the volume and price of shares transacted by the company itself across various markets over several days. This directly corresponds to the definition of 'Transaction in Own Shares' (share repurchase/issuance). The corresponding code is POS.
2020-09-15 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled 'Monthly information regarding the total number of voting rights and total number of shares of the Company' and explicitly references Article 223-16 of the AMF General Regulations. It provides a snapshot of the total number of shares and voting rights as of a specific date (August 31, 2020). This type of periodic disclosure regarding share capital structure and voting power does not fit neatly into the primary financial report categories (10-K, IR, ER) or specific corporate actions (DIV, SHA, POS). It is a mandatory regulatory disclosure concerning ownership structure. Since there is no specific code for 'Voting Rights/Share Capital Disclosure', the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a standard, periodic regulatory update.
2020-09-14 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital), referencing Article 223-16 of the AMF General Regulation. It provides a table detailing the total number of shares and voting rights as of August 31, 2020. This content directly relates to changes in the capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a specific regulatory filing (RNS). However, since it explicitly details the total number of shares and voting rights, SHA is the most precise fit among the provided options, as it covers capital structure changes, which includes the basis for voting rights calculation. It is not a general earnings release (ER), an interim report (IR), or a director's dealing (DIRS). Given the specific nature of reporting total shares and voting rights, SHA is selected over the general RNS.
2020-09-14 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Ipsen dated September 14, 2020, announcing that they will present 17 abstracts, including pivotal Phase III data (CheckMate -9ER), at the upcoming European Society for Medical Oncology (ESMO) 2020 Virtual Congress. This is an announcement about scientific data being presented at a conference, not the full financial report (10-K), an interim financial report (IR), or a general earnings release (ER). It is a communication aimed at investors and the public regarding research progress and upcoming presentations. This type of announcement, detailing scientific findings and upcoming presentations, is best classified as an Investor Presentation (IP) if it were the presentation itself, but since it is a press release *about* presentations, and it doesn't fit other specific categories like DIV, DIRS, or MANG, it falls under the general category for corporate news releases that are not strictly financial results or regulatory filings. However, given the focus on presenting detailed clinical trial data and strategy to the investment community, 'Investor Presentation' (IP) is the closest fit for the *content type* being highlighted, even though the format is a press release. If the document were purely a regulatory announcement of a report release, RPA would apply, but this is substantive news about data. Given the options, and the focus on presenting data to investors/medical community, IP is the most appropriate classification for the substance being communicated, although RNS is a possible fallback. Since it details specific data points and a schedule of presentations, it functions similarly to an investor presentation summary. I will select IP as the primary classification based on content focus.
2020-09-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.